Endo Valuation

Is NDOI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NDOI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NDOI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NDOI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NDOI?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for NDOI. This is calculated by dividing NDOI's market cap by their current preferred multiple.
What is NDOI's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$1.91b

NDOI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.3x
Enterprise Value/EBITDA	20.4x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does NDOI's PE Ratio compare to its peers?

The above table shows the PE ratio for NDOI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	20.4x
LGND Ligand Pharmaceuticals	42.2x	25.6%	US$1.8b
INVA Innoviva	8.3x	n/a	US$1.2b
AMPH Amphastar Pharmaceuticals	14x	14.1%	US$2.3b
PBH Prestige Consumer Healthcare	17.2x	5.1%	US$3.5b
NDOI Endo	0.5x	n/a	US$1.9b

Price-To-Earnings vs Peers: NDOI is good value based on its Price-To-Earnings Ratio (0.5x) compared to the peer average (20.4x).

Price to Earnings Ratio vs Industry

How does NDOI's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	23.6%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	23.6%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: NDOI is good value based on its Price-To-Earnings Ratio (0.5x) compared to the US Pharmaceuticals industry average (19.1x).

Price to Earnings Ratio vs Fair Ratio

What is NDOI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NDOI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	0.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NDOI's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.